Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.64 +0.94 (+2.20%)
Streaming Delayed Price Updated: 10:00 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
News headline image
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
News headline image
Exelixis Stock Sees Rising Relative Strength Rating ↗
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
News headline image
Analyst Expectations for Exelixis's Future ↗
 
Via Benzinga
News headline image
Exelixis (EXEL) Q2 2023 Earnings Call Transcript ↗
EXEL earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
2 Biotech Growth Stocks I'd Buy Right Now ↗
Both drugmakers seem to have a bright future ahead. 
Via The Motley Fool
News headline image
8 Analysts Have This to Say About Exelixis ↗
 
Via Benzinga
News headline image
3 Biotech Stocks You’ll Regret Not Buying Soon ↗
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗
 
Via Benzinga
News headline image
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil ↗
There is opportunity in a crisis. Key biotech stocks amid turmoil could be the greatest deals on the market today. 
Via InvestorPlace
News headline image
Exelixis (EXEL) Q1 2023 Earnings Call Transcript ↗
EXEL earnings call for the period ending March 31, 2023. 
Via The Motley Fool
News headline image
Exelixis: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
News headline image
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
News headline image
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023 ↗
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
News headline image
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
3 No-Brainer Stocks to Buy With $200 Right Now ↗
A modest amount of money can go a long way when it's invested in game-changing businesses. 
Via The Motley Fool
News headline image
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
The Smartest Stocks to Buy With $20 Right Now and Hold Forever ↗
These companies can take investors on a lucrative ride, and all for the price of a few lattes. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
Companies that don't make a lot of noise can still make you a lot of money. 
Via The Motley Fool
News headline image
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond ↗
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
News headline image
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
News headline image
Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip ↗
A sizable dip in the innovation-driven Nasdaq Composite is the perfect excuse for investors to pounce on some phenomenal deals. 
Via The Motley Fool
News headline image
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns ↗
Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,  
Via Benzinga
News headline image
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
From Farallon Capital Management L.L.C.
Via Business Wire
News headline image
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.